ASX News

Telix Pharmaceuticals Receives $11.4M R&D Tax Refund

Melbourne (Australia) – 21st July 2020. Telix Pharmaceuticals announces it has received an A$11.4M R&D tax refund in relation to eligible Australian and international R&D activities.

Telix Pharmaceuticals Limited is pleased to announce that it has received an A$11.4M R&D tax refund in relation to eligible Australian and international R&D activities undertaken by the Company in the year ended 31st December 2019.

To read the full media release please click here.